Sansum Diabetes Research Institute

DEDICATED TO IMPROVING THE LIVES OF PEOPLE IMPACTED BY DIABETES THROUGH RESEARCH, EDUCATION AND CARE.

RESEARCHRESEARCH TYPE 1 DIABETES:SANSUM DIABETES RESEARCH INSTITUTE (SDRI) IS A GLOBAL LEADER IN ADVANCING RESEARCH, EDUCATION, AND CLINICAL CARE TO THOSE IMPACTED BY TYPE 1 DIABETES (T1D). SDRI IS A PREFERRED SITE FOR CLINICAL TRIALS, A TESTAMENT TO OUR EXCEPTIONAL RESEARCH CAPABILITIES AND COMMITMENT TO ADVANCING DIABETES CARE. IN 2023, SDRI CONDUCTED 29 CLINICAL RESEARCH TRIALS, AND ENGAGED OVER 700 PARTICIPANTS. CURRENT INDUSTRY PARTNERS INCLUDE ABBOTT, DEXCOM, INSULET, ELI LILLY, MANNKIND, MEDTRONIC DIABETES, NOVO NORDISK, SANOFI, TANDEM DIABETES CARE, AND MORE.AS A PREFERRED INDUSTRY PARTNER, SDRI IS COMMITTED TO CONDUCTING PIVOTAL CLINICAL RESEARCH STUDIES TO EVALUATE THE ACCURACY AND EFFICACY OF DIABETES MANAGEMENT DEVICES, INCLUDING CONTINUOUS GLUCOSE MONITORS AND INSULIN PUMPS. THESE ADVANCEMENTS HAVE REVOLUTIONIZED T1D MANAGEMENT BY PROVIDING REAL-TIME ADJUSTMENTS AND REDUCING THE MENTAL BURDEN OF LIVING WITH DIABETES. SDRI WILL CONTINUE PARTNERING WITH INDUSTRY TO CREATE THE BEST QUALITY OF LIFE POSSIBLE FOR THOSE LIVING WITH DIABETES.SDRI SERVED AS A CLINICAL SITE IN THE TRIALS FOR MEDTRONICS CLOSED-LOOP TECHNOLOGY, TANDEM DIABETES CONTROL- IQ AND BASAL-IQ TECHNOLOGY, AND INSULETS AUTOMATED INSULIN DELIVERY SYSTEM OMNIPOD 5.GIVEN THAT INSULIN REMAINS A CORNERSTONE IN T1D MANAGEMENT, SDRI CONDUCTS COMPREHENSIVE STUDIES TO EXPLORE NOVEL INSULIN FORMULATIONS, DELIVERY METHODS, AND DOSING STRATEGIES. SDRI HAS PARTICIPATED IN KEY DRUG DEVELOPMENT CLINICAL TRIALS INCLUDING MANNKIND'S AFREZZA INHALED INSULIN, ELI LILLY'S ONCE-WEEKLY BASAL INSULIN AND GLP-1 INHIBITORS, NOVO NORDISK'S FAST ACTING INSULIN FIASP AND COMPARING TRESIBA AND LANTUS OVER LONG-HAUL TRAVEL, AND A COMPARISON BETWEEN SANOFI'S DRUGS, TOUJEO AND LANTUS. BY STAYING AT THE FOREFRONT OF INSULIN RESEARCH, WE AIM TO OPTIMIZE TREATMENT OUTCOMES AND MINIMIZE THE BURDEN OF DIABETES MANAGEMENT.SDRIS MEANINGFUL RESEARCH PROVIDES VALUABLE INSIGHTS THAT ENHANCE THE QUALITY OF LIFE FOR INDIVIDUALS LIVING WITH T1D.RESEARCH TYPE 2 DIABETES:SDRI IS COMMITTED TO CONDUCTING GROUNDBREAKING RESEARCH TO FIND THE NEXT BREAKTHROUGH IN MANAGING TYPE 2 DIABETES (T2D), AS IT IS ONE OF THE FASTEST GROWING CHRONIC DISEASES IN THE WORLD. WE UNDERSTAND THAT EDUCATION PLAYS A VITAL ROLE IN LIVING WITH T2D. OUR TEAM IS COMMITTED TO OFFERING A HOLISTIC APPROACH IN MANAGING T2D WITH A SPECIAL INTEREST IN ADVANCING EDUCATION AND RESEARCH OPPORTUNITIES FOR UNDERSERVED COMMUNITIES.IN 2023, SDRI CONDUCTED EDUCATION, DIABETES IN PREGNANCY, AND DEVICE CLINICAL RESEARCH STUDIES THAT HELPED IMPROVE THE CARE AND MANAGEMENT OF TYPE 2 DIABETES, LEADING TO BETTER HEALTH OUTCOMES AND QUALITY OF LIFE FOR PATIENTS. SDRI PROUDLY PARTNERED WITH ROOTED SANTA BARBARA COUNTY IN 2023 IN THE PRODUCTION OF A CULTURALLY TAILORED, PLANT-BASED NUTRITION CURRICULUM THAT AIMS TO IMPROVE THE HEALTH AND HEALTH EQUITY OF SOCIOECONOMICALLY DISADVANTAGED POPULATIONS IN SANTA BARBARA. SDRI EQUIPPED OUR COMMUNITY HEALTH WORKERS WITH NEARLY 30 HOURS OF COMPREHENSIVE TRAINING AT THE UNIVERSITY OF SOUTHERN CALIFORNIA IN 2023, WHERE THEY GAINED ESSENTIAL KNOWLEDGE AND SKILLS TO SUPPORT CLINICAL RESEARCH RECRUITMENT, ENSURE MEDICATION SAFETY, AND IMPROVE DIABETES MANAGEMENT WITH THE LOCAL LATINO COMMUNITY. IN 2023, SDRI PROVIDED INDIVIDUAL CARE TO 87 UNDERREPRESENTED LATINOS WHO WERE LIVING WITH PREDIABETES, TYPE 2 DIABETES, OR DIABETES IN PREGNANCY. SDRI CONTINUED TO LEAD THE SANTA BARBARA NUTRITION HEALTH COALITION IN 2023 IN DEVELOPING AND IMPLEMENTING INNOVATIVE, CULTURALLY SENSITIVE, COMMUNITY-BASED, AND EVIDENCE-BASED NUTRITION INTERVENTION PROGRAMS TO IMPROVE HEALTH AND HEALTH EQUITY OF VULNERABLE POPULATIONS LIVING IN SANTA BARBRA COUNTY.

RESEARCHRESEARCH TYPE 1 DIABETES:SANSUM DIABETES RESEARCH INSTITUTE (SDRI) IS A GLOBAL LEADER IN ADVANCING RESEARCH, EDUCATION, AND CLINICAL CARE TO THOSE IMPACTED BY TYPE 1 DIABETES (T1D). SDRI IS A PREFERRED SITE FOR CLINICAL TRIALS, A TESTAMENT TO OUR EXCEPTIONAL RESEARCH CAPABILITIES AND COMMITMENT TO ADVANCING DIABETES CARE. IN 2023, SDRI CONDUCTED 29 CLINICAL RESEARCH TRIALS, AND ENGAGED OVER 700 PARTICIPANTS. CURRENT INDUSTRY PARTNERS INCLUDE ABBOTT, DEXCOM, INSULET, ELI LILLY, MANNKIND, MEDTRONIC DIABETES, NOVO NORDISK, SANOFI, TANDEM DIABETES CARE, AND MORE.AS A PREFERRED INDUSTRY PARTNER, SDRI IS COMMITTED TO CONDUCTING PIVOTAL CLINICAL RESEARCH STUDIES TO EVALUATE THE ACCURACY AND EFFICACY OF DIABETES MANAGEMENT DEVICES, INCLUDING CONTINUOUS GLUCOSE MONITORS AND INSULIN PUMPS. THESE ADVANCEMENTS HAVE REVOLUTIONIZED T1D MANAGEMENT BY PROVIDING REAL-TIME ADJUSTMENTS AND REDUCING THE MENTAL BURDEN OF LIVING WITH DIABETES. SDRI WILL CONTINUE PARTNERING WITH INDUSTRY TO CREATE THE BEST QUALITY OF LIFE POSSIBLE FOR THOSE LIVING WITH DIABETES.SDRI SERVED AS A CLINICAL SITE IN THE TRIALS FOR MEDTRONICS CLOSED-LOOP TECHNOLOGY, TANDEM DIABETES CONTROL- IQ AND BASAL-IQ TECHNOLOGY, AND INSULETS AUTOMATED INSULIN DELIVERY SYSTEM OMNIPOD 5.GIVEN THAT INSULIN REMAINS A CORNERSTONE IN T1D MANAGEMENT, SDRI CONDUCTS COMPREHENSIVE STUDIES TO EXPLORE NOVEL INSULIN FORMULATIONS, DELIVERY METHODS, AND DOSING STRATEGIES. SDRI HAS PARTICIPATED IN KEY DRUG DEVELOPMENT CLINICAL TRIALS INCLUDING MANNKIND'S AFREZZA INHALED INSULIN, ELI LILLY'S ONCE-WEEKLY BASAL INSULIN AND GLP-1 INHIBITORS, NOVO NORDISK'S FAST ACTING INSULIN FIASP AND COMPARING TRESIBA AND LANTUS OVER LONG-HAUL TRAVEL, AND A COMPARISON BETWEEN SANOFI'S DRUGS, TOUJEO AND LANTUS. BY STAYING AT THE FOREFRONT OF INSULIN RESEARCH, WE AIM TO OPTIMIZE TREATMENT OUTCOMES AND MINIMIZE THE BURDEN OF DIABETES MANAGEMENT.SDRIS MEANINGFUL RESEARCH PROVIDES VALUABLE INSIGHTS THAT ENHANCE THE QUALITY OF LIFE FOR INDIVIDUALS LIVING WITH T1D.RESEARCH TYPE 2 DIABETES:SDRI IS COMMITTED TO CONDUCTING GROUNDBREAKING RESEARCH TO FIND THE NEXT BREAKTHROUGH IN MANAGING TYPE 2 DIABETES (T2D), AS IT IS ONE OF THE FASTEST GROWING CHRONIC DISEASES IN THE WORLD. WE UNDERSTAND THAT EDUCATION PLAYS A VITAL ROLE IN LIVING WITH T2D. OUR TEAM IS COMMITTED TO OFFERING A HOLISTIC APPROACH IN MANAGING T2D WITH A SPECIAL INTEREST IN ADVANCING EDUCATION AND RESEARCH OPPORTUNITIES FOR UNDERSERVED COMMUNITIES.IN 2023, SDRI CONDUCTED EDUCATION, DIABETES IN PREGNANCY, AND DEVICE CLINICAL RESEARCH STUDIES THAT HELPED IMPROVE THE CARE AND MANAGEMENT OF TYPE 2 DIABETES, LEADING TO BETTER HEALTH OUTCOMES AND QUALITY OF LIFE FOR PATIENTS. SDRI PROUDLY PARTNERED WITH ROOTED SANTA BARBARA COUNTY IN 2023 IN THE PRODUCTION OF A CULTURALLY TAILORED, PLANT-BASED NUTRITION CURRICULUM THAT AIMS TO IMPROVE THE HEALTH AND HEALTH EQUITY OF SOCIOECONOMICALLY DISADVANTAGED POPULATIONS IN SANTA BARBARA. SDRI EQUIPPED OUR COMMUNITY HEALTH WORKERS WITH NEARLY 30 HOURS OF COMPREHENSIVE TRAINING AT THE UNIVERSITY OF SOUTHERN CALIFORNIA IN 2023, WHERE THEY GAINED ESSENTIAL KNOWLEDGE AND SKILLS TO SUPPORT CLINICAL RESEARCH RECRUITMENT, ENSURE MEDICATION SAFETY, AND IMPROVE DIABETES MANAGEMENT WITH THE LOCAL LATINO COMMUNITY. IN 2023, SDRI PROVIDED INDIVIDUAL CARE TO 87 UNDERREPRESENTED LATINOS WHO WERE LIVING WITH PREDIABETES, TYPE 2 DIABETES, OR DIABETES IN PREGNANCY. SDRI CONTINUED TO LEAD THE SANTA BARBARA NUTRITION HEALTH COALITION IN 2023 IN DEVELOPING AND IMPLEMENTING INNOVATIVE, CULTURALLY SENSITIVE, COMMUNITY-BASED, AND EVIDENCE-BASED NUTRITION INTERVENTION PROGRAMS TO IMPROVE HEALTH AND HEALTH EQUITY OF VULNERABLE POPULATIONS LIVING IN SANTA BARBRA COUNTY.

CLINICAL CARE:SDRI PROVIDED CLINICAL CARE IN 3 AREAS: DIABETES IN PREGNANCY, PEDIATRIC AND ADULT ENDOCRINOLOGY.FOR NEARLY 50 YEARS, SDRI HAS REMAINED A THOUGHT LEADER FOR DIABETES DURING PREGNANCY. OUR TEAM IS COMMITTED TO CONDUCTING GROUNDBREAKING RESEARCH TO HELP REDUCE RISKS FOR A WOMANS PREGNANCY THAT IS COMPLICATED BY DIABETES. IN 2023, SDRI PROVIDED PATIENT CARE TO 120 PATIENTS WHOSE PREGNANCY WAS COMPLICATED BY ANY FORM OF DIABETES INCLUDING PREDIABETES, GESTATIONAL DIABETES, TYPE 1 DIABETES, AND TYPE 2 DIABETES. DURING APPOINTMENTS OUR ELITE TEAM OFFERED PATIENTS INNOVATIVE TOOLS TO HELP STABILIZE BLOOD GLUCOSE LEVELS TO LIMIT COMPLICATIONS TO BOTH THE EXPECTANT MOTHER AND BABY. SDRI PARTNERS WITH THE SANTA BARBARA COUNTY HEALTH DEPARTMENT TO ENSURE THAT UNDERREPRESENTED LATINA WOMEN RECEIVE SUPERIOR CARE FOR THEIR PREGNANCY COMPLICATED BY DIABETES. IN 2023, SDRI INITIATED THREE TRANSFORMATIONAL RESEARCH STUDIES CRITICAL TO DIAGNOSING AND MANAGING DIABETES IN PREGNANCY, IMPROVING HEALTH OUTCOMES, AND ENHANCING THE LIFESPAN OF MOTHERS AND THEIR BABIES. SDRI SERVED AS A CLINICAL RESEARCH SITE FOR THE FIRST AT HOME USE OF A PREGNANCY SPECIFIC CLOSED-LOOP SYSTEM. IN COLLABORATION WITH HARVARD JOHN A. PAULSON SCHOOL OF ENGINEERING AND APPLIED SCIENCES AT HARVARD UNIVERSITY, ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, AND THE MAYO CLINIC. THIS STUDY, PUBLISHED IN DIABETES CARE, DEMONSTRATED THAT IN 2023, THE TRIAL DEMONSTRATED THAT THE SYSTEM IMPROVED BLOOD SUGAR CONTROL WITHOUT INCREASING RISKS, INDICATING IT CAN SAFELY HELP PREGNANT WOMEN MANAGE THEIR BLOOD SUGAR TARGETS AT HOME. THE STUDY RESULTS WERE PRESENTED AT THE ADVANCED TECHNOLOGIES AND TREATMENTS FOR DIABETES 2023 INTERNATIONAL DIABETES CONGRESS. SDRI IS PROUD TO PLAY A CRITICAL ROLE IN ENSURING THE HEALTH SPAN AND LIFESPAN OF WOMEN WHOSE PREGNANCIES ARE COMPLICATED BY DIABETES, AS WELL AS THEIR BABIES.

CLINICAL CARE:SDRI PROVIDED CLINICAL CARE IN 3 AREAS: DIABETES IN PREGNANCY, PEDIATRIC AND ADULT ENDOCRINOLOGY.FOR NEARLY 50 YEARS, SDRI HAS REMAINED A THOUGHT LEADER FOR DIABETES DURING PREGNANCY. OUR TEAM IS COMMITTED TO CONDUCTING GROUNDBREAKING RESEARCH TO HELP REDUCE RISKS FOR A WOMANS PREGNANCY THAT IS COMPLICATED BY DIABETES. IN 2023, SDRI PROVIDED PATIENT CARE TO 120 PATIENTS WHOSE PREGNANCY WAS COMPLICATED BY ANY FORM OF DIABETES INCLUDING PREDIABETES, GESTATIONAL DIABETES, TYPE 1 DIABETES, AND TYPE 2 DIABETES. DURING APPOINTMENTS OUR ELITE TEAM OFFERED PATIENTS INNOVATIVE TOOLS TO HELP STABILIZE BLOOD GLUCOSE LEVELS TO LIMIT COMPLICATIONS TO BOTH THE EXPECTANT MOTHER AND BABY. SDRI PARTNERS WITH THE SANTA BARBARA COUNTY HEALTH DEPARTMENT TO ENSURE THAT UNDERREPRESENTED LATINA WOMEN RECEIVE SUPERIOR CARE FOR THEIR PREGNANCY COMPLICATED BY DIABETES. IN 2023, SDRI INITIATED THREE TRANSFORMATIONAL RESEARCH STUDIES CRITICAL TO DIAGNOSING AND MANAGING DIABETES IN PREGNANCY, IMPROVING HEALTH OUTCOMES, AND ENHANCING THE LIFESPAN OF MOTHERS AND THEIR BABIES. SDRI SERVED AS A CLINICAL RESEARCH SITE FOR THE FIRST AT HOME USE OF A PREGNANCY SPECIFIC CLOSED-LOOP SYSTEM. IN COLLABORATION WITH HARVARD JOHN A. PAULSON SCHOOL OF ENGINEERING AND APPLIED SCIENCES AT HARVARD UNIVERSITY, ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, AND THE MAYO CLINIC. THIS STUDY, PUBLISHED IN DIABETES CARE, DEMONSTRATED THAT IN 2023, THE TRIAL DEMONSTRATED THAT THE SYSTEM IMPROVED BLOOD SUGAR CONTROL WITHOUT INCREASING RISKS, INDICATING IT CAN SAFELY HELP PREGNANT WOMEN MANAGE THEIR BLOOD SUGAR TARGETS AT HOME. THE STUDY RESULTS WERE PRESENTED AT THE ADVANCED TECHNOLOGIES AND TREATMENTS FOR DIABETES 2023 INTERNATIONAL DIABETES CONGRESS. SDRI IS PROUD TO PLAY A CRITICAL ROLE IN ENSURING THE HEALTH SPAN AND LIFESPAN OF WOMEN WHOSE PREGNANCIES ARE COMPLICATED BY DIABETES, AS WELL AS THEIR BABIES.

EDUCATION AND COMMUNITY OUTREACH:CONTINUING THE LEGACY OF FOUNDER WILLIAM SANSUM, MD, SDRI HAS REMAINED COMMITTED TO PROVIDING LIFE-SAVING DIABETES CARE TO THE COMMUNITY, ENSURING THAT COST IS NEVER A BARRIER. TO EXPAND OUR REACH IN SANTA BARBARA AND HELP ADDRESS DISPARITIES IN ACCESS TO CARE, SDRI BEGAN HOSTING MOBILE CLINICS IN 2023 AT VARIOUS LOCATIONS AND EVENTS THROUGHOUT THE CITY. THESE MOBILE CLINICS, RUN BY BILINGUAL COMMUNITY HEALTH WORKERS, PROVIDE AN OPPORTUNITY FOR ATTENDEES TO RECEIVE CULTURALLY APPROPRIATE DIABETES EDUCATION, TEST BLOOD GLUCOSE LEVELS, CALCULATE THEIR BODY MASS INDEX, AND GET CONNECTED TO NECESSARY RESOURCES.RECOGNIZING A GROWING NEED FOR DIABETES TREATMENT AND PREVENTION WITHIN THE LOCAL LATINO POPULATION, IN 2023, SDRI SECURED A PERMANENT SPACE AT LA CASA DE LA RAZA, A PLACE WHERE SANTA BARBARAS LATINO COMMUNITY CAN CONGREGATE, HOST EVENTS, ATTEND WORKSHOPS, AND RECEIVE ASSISTANCE FROM SEVERAL NONPROFITS. IN ADDITION TO HOSTING CLINICS WEEKLY AT LA CASA, SDRI PROVIDED HEALTH SCREENINGS AND DIABETES EDUCATION AT SEVERAL OTHER LOCATIONS THROUGHOUT THE YEAR INCLUDING THE EASTSIDE LIBRARY, CARPINTERIA CHILDRENS PROJECT, AND THE SENIOR EXPO OF SANTA BARBARA AT EARL WARREN SHOWGROUNDS.SDRI CREATED A SERIES OF EDUCATION CLASSES FOR THE LATINO POPULATION INCLUDING: OCHO PASOS - 8 WEEKS TO HEALTHY LIVING, SEMILLAS DE CAMBIO - OCHO PASOS DURING PREGNANCY, AND GRUPO DE APOYO SPANISH PROGRAM FOR INDIVIDUALS LIVING WITH, OR AT RIS OF DEVELOPING, TYPE 2 DIABETES.COMMUNITY HEALTH WORKERS PLAY A VITAL ROLE IN OUR EFFORTS TO PROMOTE HEALTH EQUITY BY BRIDGING GAPS IN HEALTHCARE ACCESS AND EDUCATION. THESE DEDICATED INDIVIDUALS ARE TRAINED AT SDRI TO BECOME SPECIALISTS IN DIABETES AND RESEARCH PROGRAMS, WORKING CLOSELY WITH COMMUNITY MEMBERS TO PROVIDE CULTURALLY COMPETENT CARE, SUPPORT SELF-MANAGEMENT PRACTICES, AND EMPOWER INDIVIDUALS TO TAKE CONTROL OF THEIR HEALTH AND DIABETES. IN 2023, SDRI OFFERED ONETALK A PROGRAM WHERE PARTICIPANTS IMPACTED BY T!D SHARE THEIR IDEAS, EXPERIENCE AND EXPLORE WAYS TO ENHANCE THEIR HEALTH AND LIFESTYLE; LADATALK A PROGRAM FOR THOSE IMPACTED BY LATENT AUTOIMMUNE DIABETES IN ADULTS (LADA) AND OFFERS INSIGHTS, CONNECTIONS, AND UP-TO-DATE INFORMATION ON CLINICAL RESEARCH TRIALS FROM SDRIS CLINICAL RESEARCH TEAM; FAMILY OUTREACH EVENTS - QUARTERLY EVENTS TO SUPPORT THE DIABETES COMMUNITY, WHERE FAMILIES CONNECT WITH OTHERS LIVING WITH TYPE 1 DIABETES, SHARE EXPERIENCES, AND LEARN ABOUT CURRENT CLINICAL TRIALS FROM SDRIS CLINICAL RESEARCH TEAM.

EDUCATION AND COMMUNITY OUTREACH:CONTINUING THE LEGACY OF FOUNDER WILLIAM SANSUM, MD, SDRI HAS REMAINED COMMITTED TO PROVIDING LIFE-SAVING DIABETES CARE TO THE COMMUNITY, ENSURING THAT COST IS NEVER A BARRIER. TO EXPAND OUR REACH IN SANTA BARBARA AND HELP ADDRESS DISPARITIES IN ACCESS TO CARE, SDRI BEGAN HOSTING MOBILE CLINICS IN 2023 AT VARIOUS LOCATIONS AND EVENTS THROUGHOUT THE CITY. THESE MOBILE CLINICS, RUN BY BILINGUAL COMMUNITY HEALTH WORKERS, PROVIDE AN OPPORTUNITY FOR ATTENDEES TO RECEIVE CULTURALLY APPROPRIATE DIABETES EDUCATION, TEST BLOOD GLUCOSE LEVELS, CALCULATE THEIR BODY MASS INDEX, AND GET CONNECTED TO NECESSARY RESOURCES.RECOGNIZING A GROWING NEED FOR DIABETES TREATMENT AND PREVENTION WITHIN THE LOCAL LATINO POPULATION, IN 2023, SDRI SECURED A PERMANENT SPACE AT LA CASA DE LA RAZA, A PLACE WHERE SANTA BARBARAS LATINO COMMUNITY CAN CONGREGATE, HOST EVENTS, ATTEND WORKSHOPS, AND RECEIVE ASSISTANCE FROM SEVERAL NONPROFITS. IN ADDITION TO HOSTING CLINICS WEEKLY AT LA CASA, SDRI PROVIDED HEALTH SCREENINGS AND DIABETES EDUCATION AT SEVERAL OTHER LOCATIONS THROUGHOUT THE YEAR INCLUDING THE EASTSIDE LIBRARY, CARPINTERIA CHILDRENS PROJECT, AND THE SENIOR EXPO OF SANTA BARBARA AT EARL WARREN SHOWGROUNDS.SDRI CREATED A SERIES OF EDUCATION CLASSES FOR THE LATINO POPULATION INCLUDING: OCHO PASOS - 8 WEEKS TO HEALTHY LIVING, SEMILLAS DE CAMBIO - OCHO PASOS DURING PREGNANCY, AND GRUPO DE APOYO SPANISH PROGRAM FOR INDIVIDUALS LIVING WITH, OR AT RIS OF DEVELOPING, TYPE 2 DIABETES.COMMUNITY HEALTH WORKERS PLAY A VITAL ROLE IN OUR EFFORTS TO PROMOTE HEALTH EQUITY BY BRIDGING GAPS IN HEALTHCARE ACCESS AND EDUCATION. THESE DEDICATED INDIVIDUALS ARE TRAINED AT SDRI TO BECOME SPECIALISTS IN DIABETES AND RESEARCH PROGRAMS, WORKING CLOSELY WITH COMMUNITY MEMBERS TO PROVIDE CULTURALLY COMPETENT CARE, SUPPORT SELF-MANAGEMENT PRACTICES, AND EMPOWER INDIVIDUALS TO TAKE CONTROL OF THEIR HEALTH AND DIABETES. IN 2023, SDRI OFFERED ONETALK A PROGRAM WHERE PARTICIPANTS IMPACTED BY T!D SHARE THEIR IDEAS, EXPERIENCE AND EXPLORE WAYS TO ENHANCE THEIR HEALTH AND LIFESTYLE; LADATALK A PROGRAM FOR THOSE IMPACTED BY LATENT AUTOIMMUNE DIABETES IN ADULTS (LADA) AND OFFERS INSIGHTS, CONNECTIONS, AND UP-TO-DATE INFORMATION ON CLINICAL RESEARCH TRIALS FROM SDRIS CLINICAL RESEARCH TEAM; FAMILY OUTREACH EVENTS - QUARTERLY EVENTS TO SUPPORT THE DIABETES COMMUNITY, WHERE FAMILIES CONNECT WITH OTHERS LIVING WITH TYPE 1 DIABETES, SHARE EXPERIENCES, AND LEARN ABOUT CURRENT CLINICAL TRIALS FROM SDRIS CLINICAL RESEARCH TEAM.